News|Articles|July 1, 2009

FDA Pipeline preview, July 2009 (bucindolol, botulinum toxin type A, rivaroxaban, quetiapine, olanzapine, ziprasidone, ofatumumab, pegloticase, pralatrexate, melphalan, paclitaxel)

Recent FDA action (through July 2009) related to bucindolol, botulinum toxin type A, rivaroxaban, quetiapine, olanzapine, ziprasidone, ofatumumab, pegloticase, pralatrexate, melphalan, and paclitaxel

Complete response

Recommended for approval

Fast-track designations

Orphan drug designations

Newsletter

Get the latest industry news, event updates, and more from Managed healthcare Executive.


Latest CME